Background and Purpose-Few studies have assessed the association of HDL (high-density lipoprotein) cholesterol with stroke risk among patients with type 2 diabetes mellitus. We aimed to investigate the association of HDL cholesterol with total and type-specific stroke risk in patients with type 2 diabetes mellitus. Methods-We performed a retrospective cohort study of 27 113 blacks and 40 431 whites with type 2 diabetes mellitus. Cox proportional hazards regression models were used to estimate the association of different levels of HDL cholesterol with stroke risk. Results-During a mean follow-up period of 3.0 years, 8496 patients developed stroke (8048 ischemic and 448 hemorrhagic).
L ow level of HDL (high-density lipoprotein) cholesterol is a well-established risk factor for cardiovascular diseases (CVD). 1 A recent meta-analysis of individual data from 61 prospective studies found a strong inverse association of HDL cholesterol with CVD mortality. 1 However, the association between HDL cholesterol and risk of total and type-specific stroke is less clear. Both a meta-analysis and a Japanese study among the general population found a positive association between HDL cholesterol and intracerebral hemorrhage, 2, 3 whereas other studies reported an inverse association between HDL cholesterol and the risk of total stroke. 4, 5 Diabetes mellitus and lipoprotein abnormalities are 2 important public health problems in the United States. 6 Over 50% of people aged ≥18 years who have diabetes mellitus are also affected by lipoprotein abnormalities. 7 Low levels of HDL cholesterol as one of the major contributors for lipoprotein abnormalities have been found to be associated with an increased risk of CVD among patients with type 2 diabetes mellitus. [8] [9] [10] However, few studies have assessed whether low levels of HDL cholesterol were also associated with an increased risk of stroke among patients with type 2 diabetes mellitus. The aim of the present study was to evaluate the role of HDL cholesterol on the risks of total and type-specific stroke events in patients with type 2 diabetes mellitus.
Methods

Study Participants
The data that support the findings of this study are available from the corresponding author on reasonable request. Data on patients with type 2 diabetes mellitus in the LEAD cohort study (Louisiana
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Experiment Assessing Diabetes outcomes) were obtained through the Research Action for Health Network (REACHnet). The dataset included electronic health record data for the study cohort between January 1, 2013, and October 10, 2017. For the present study, data from 3 REACHnet partner health systems were included in the final pooled analysis. A unique global identifier was used to link records across the 3 partners to avoid duplication of individual patients in the pooled dataset. Totally 18 706 patients were identified as duplicates across the 3 partner health systems. The definition of type 2 diabetes mellitus in the present study was formulated according to the Surveillance Prevention, and Management of Diabetes Mellitus (SUPREME-DM) definitions as follows 11 : (1) 1 or more of the International Classification of Disease, Ninth Revision, Clinical Modification (ICD-9-CM) codes and Tenth Revision, Clinical Modification (ICD-10-CM) codes for type 2 diabetes mellitus associated with in-patient encounters; (2) 2 or more ICD codes associated with out-patient encounters on different days within 2 years; (3) combination of 2 or more of the following associated with out-patient encounters on different days within 2 years: (1) ICD codes; (2) fasting glucose level ≥126 mg/dL; (3) 2-hour glucose level ≥200 mg/dL; (4) random glucose ≥200 mg/dL; (5) hemoglobin A1c (HbA1c) ≥6.5%; and (6) prescription for an antidiabetic medications. A total of 107 562 patients between the ages of 30 and 94 years were identified. After the exclusion of patients with incomplete data, the present study included 67 544 patients with diabetes mellitus (40 431 whites and 27 113 blacks). Compared with patients with diabetes excluded in the present study, the patients included in the present study were similar in age (66.5±12.1 versus 66.3±12.5 years of age), included more blacks (40.1% versus 36.2%), and included slightly fewer men in percentage (47.5% versus 49.1%). The study and analysis plan were approved by the Pennington Biomedical Research Center, Tulane University, and Ochsner Health System Institutional Review Boards. We used an electronic dataset compiled from medical records but not containing personally identifiable information except date of birth; thus, we did not obtain written informed consent from patients in the observational study cohort.
Baseline Measurements
The National Patient-Centered Clinical Research Network (PCORnet) common data model is a specification that defines a standard organization and representation of data for the PCORnet distributed research network. 12 Patients' data extracted from this common data model for the present study included date of birth, age of diabetes mellitus diagnosis, race/ethnicity, sex, date of examination, weight, height, body mass index, blood pressure, tobacco use, diagnosis of various diseases and date of diagnosis, laboratory test date, total cholesterol, triglycerides, HDL cholesterol, LDL (low-density lipoprotein) cholesterol, glycosylated HbA1c, estimated glomerular filtration rate, and medication history, such as antihypertensive drugs, glucose-lowering drugs, and lipid-lowering drugs. These data elements were collected starting from date of the diabetes mellitus diagnosis (baseline). Using smoking status reported at each clinical visit, we classified the patients into 3 groups: current smokers, ever smokers, and never smokers. The estimated glomerular filtration rate was estimated using the modification of diet in renal disease. 
Follow-Up
We created the follow-up database in electronic form by using the number assigned to every patient who visited the health system as a unique patient identifier. The updated mean value of HDL cholesterol was calculated for each participant from baseline to each year of follow-up. For example, after 1 year, the updated mean was the average of the baseline and 1-year values, and after 3 years it was the average of baseline, 1-, 2-, and 3-year values. In case of an event occurring during follow-up, the period for estimating the updated mean value was from baseline to the year before the event occurred. The average number of HDL cholesterol measurements during the follow-up period was 3.95. Stroke (ischemic or hemorrhagic) was identified as the outcome in the present analysis. The ICD-9-CM and ICD- 10 
Statistical Analyses
Cox proportional hazards regression was used to estimate hazard ratios (HRs) for incident stroke according to levels of HDL cholesterol. HDL cholesterol was evaluated in the following 2 ways: (1) as categories (<30, 30-39.9, 40-49.9, 50-59.9, 60-69.9, 70-79.9, and ≥80 mg/dL) and (2) as a continuous variable. HDL cholesterol levels were included in the models as dummy variables, and the significance of the trend across categories of HDL cholesterol was tested in the same models by giving an ordinal numeric value for each dummy variable. The proportional hazards assumption in the Cox model was assessed with graphical methods and with models, including time-bycovariate interactions.
14 In general, all proportionality assumptions were appropriate. All analyses were first performed adjusting for age and race (model 1), and further for smoking, body mass index, systolic blood pressure, HbA1c, LDL cholesterol, triglycerides, estimated glomerular filtration rate (model 2), and finally use of antihypertensive drugs, use of glucose-lowering medications, and use of lipid-lowering medications (model 3). Statistical significance was considered to be P<0.05. All statistical analyses were performed by using IBM SPSS Statistics for Windows, version 24.0 (IBM Corp, Armonk, NY).
Results
Characteristics of the study population are presented in Table I in the online-only Data Supplement. During a mean follow-up period of 3.0 years from initial diabetes mellitus diagnosis, 8496 people developed an incident stroke event (8048 ischemic and 448 hemorrhagic).
Multivariable-adjusted (model 3) HRs for total stroke across different levels of HDL cholesterol at baseline (<30 [reference group], 30-39.9, 40-49.9, 50-59.9, 60-69.9, 70-79.9, and ≥80 mg/dL) tended to decrease both in men (P trend =0.013) and in women (P trend <0.001), as well as in men and women combined (P trend <0.001; Table 1 ). When HDL cholesterol was examined as a continuous variable, the multivariable-adjusted (model 3) HRs of total stroke for 15 mg/ dL increase of HDL cholesterol at baseline were 0.90 (95% CI, 0.86-0.94) in men, 0.89 (95% CI, 0.85-0.92) in women, and 0.89 (95% CI, 0.86-0.91) for men and women combined. When we used a mean value of HDL cholesterol, we found the same inverse association between HDL cholesterol and the risk of total stroke (Table 1) .
In the analysis of subtypes of stroke (Table 2) , we separated the outcomes into the hemorrhagic stroke and ischemic stroke. Multivariable-adjusted HRs across levels of HDL cholesterol by categories at baseline (<30, 30-39.9, 40-49.9, 50-59.9, 60-69.9, 70-79.9, and 80 mg/dL) also tended to decrease both for ischemic stroke (P trend <0.001) and for hemorrhagic stroke (P trend =0.021) in men and women combined. When HDL cholesterol was examined as a continuous variable, the Data are hazard ratios (95% CIs) unless otherwise indicated. Model 1 adjusted for age and race. Model 2 adjusted for age, race, body mass index, systolic blood pressure, HbA1c, LDL cholesterol, triglycerides, estimated GFR, and smoking. Models 3 adjusted for age, race, body mass index, systolic blood pressure, HbA1c, LDL cholesterol, triglycerides, estimated GFR, smoking, use of antihypertensive drugs, use of diabetes mellitus medications, and use of lipid-lowering agents. GFR indicates glomerular filtration rate; Hb, hemoglobin; HDL, high-density lipoprotein; and LDL, low-density lipoprotein.
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multivariable-adjusted (model 3) HRs for 15 mg/dL increase of HDL cholesterol at baseline were 0.89 (95% CI, 0.86-0.92) for ischemic stroke and 0.83 (95% CI, 0.73-0.95) for hemorrhagic stroke. When we used an updated mean value of HDL cholesterol, we found the same inverse association between HDL cholesterol and the risks of ischemic and hemorrhagic stroke ( Table 2 ). In the subgroup analyses, the significant inverse association of HDL cholesterol at baseline with the risk of total stroke was confirmed among patients with different ages, races, body mass index, HbA1c levels, never and current or past smoking, using and not using cholesterol-lowering agents, antihypertensive drugs, glucose-lowering agents, and oral hypoglycemic agents or insulin (Table 3 ). There were no significant interactions of age, race, body mass index, HbA1c level, smoking status, the use of cholesterol-lowering agents, antihypertensive drugs, glucose-lowering agents, and HDL cholesterol with the risk of total stroke (all P for interaction >0.25).
We further conducted subgroup analysis of HDL cholesterol with the risk of subarachnoid hemorrhage and intracerebral hemorrhage, respectively (Table II in the online-only Data Supplement); however, the trends were not statistically significant, likely because of the reduction in the sample sizes associated with the further stratification of the sample.
Discussion
In this large cohort study, we found that serum HDL cholesterol levels were inversely associated with the risks of total stroke, as well as the hemorrhagic and ischemic stroke among patients with type 2 diabetes mellitus. Data are hazard ratios (95% CIs) unless otherwise indicated. Model 1 adjusted for age, race and sex. Model 2 adjusted for age, race, sex, body mass index, systolic blood pressure, HbA1c, LDL cholesterol, triglycerides, estimated GFR, and smoking. Models 3 adjusted for age, race, sex, body mass index, systolic blood pressure, HbA1c, LDL cholesterol, triglycerides, estimated GFR, smoking, use of antihypertensive drugs, use of diabetes mellitus medications, and use of lipid-lowering agents. GFR indicates glomerular filtration rate; Hb, hemoglobin; HDL, high-density lipoprotein; and LDL, low-density lipoprotein.
*Since no hemorrhagic event occurred in this subgroup, we combined this group with HDL cholesterol 70-79.9 mg/dL group.
A lower level of HDL cholesterol is observed in patients with diabetes mellitus along with various metabolic disorders 15 and is also regarded as one of the components of metabolic syndrome. 16 HDL cholesterol has long been studied and considered as a potential protective factor against CVD. 17 Although LDL cholesterol can be efficiently reduced by the use of statins, there is still not a specific drug targeting HDL cholesterol on the market. Therefore, the association between HDL cholesterol and CVD or atherosclerosis is gathering more and more attention. It was previously and generally accepted that HDL cholesterol was inversely associated with the risks of CVD including stroke among the general population. The Multi-Ethnic Study of Atherosclerosis showed that although higher HDL cholesterol was associated with a lower risk of stroke in the general population, the association between HDL cholesterol and stroke risk was significant only in blacks but not in other races. 5 Another Japanese cohort found that small to medium-sized HDL cholesterol, not large HDL cholesterol was inversely associated with total stroke risk. 4 It has been noted that >50% of patients with diabetes mellitus have low HDL cholesterol. 7 Several studies have indicated an inverse association between HDL cholesterol and the risk of CVD among patients with type 2 diabetes mellitus. [8] [9] [10] However, only one Japanese study has found an inverse association of HDL cholesterol with total stroke risk among patients with type 2 diabetes mellitus in the last 10 years. 18 The present study also found an inverse association between serum HDL cholesterol levels and the risk of total stroke among patients with type 2 diabetes mellitus. In addition, we extended this inverse association among both blacks and whites, men and women, patients with nonobese and obese, never and ever or current smokers, and patients using or not using glucose-lowering, cholesterol-lowering, or antihypertensive agents.
Few studies have assessed the association between HDL cholesterol levels and the risk of hemorrhagic stroke among Data are hazard ratios (95% CIs) unless otherwise indicated. Adjusted for age, race, sex, body mass index, systolic blood pressure, HbA1c, LDL cholesterol, triglycerides, estimated GFR, smoking, use of antihypertensive drugs, use of diabetes mellitus medications, and use of lipid-lowering agents, other than the variables for stratification. All P for interaction >0.25. GFR indicates glomerular filtration rate; Hb, hemoglobin; HDL, high-density lipoprotein; and LDL, low-density lipoprotein.
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February 2019 the general population, and results remained controversial. A meta-analysis in 2013 showed that HDL cholesterol seemed to be positively associated with the risk of intracerebral hemorrhage. 2 However, another study using medical records found that HDL cholesterol values were significantly and inversely associated with aneurysmal subarachnoid hemorrhage. 19 One Finnish study did not find any associations between HDL cholesterol and the risk of hemorrhagic stroke. 20 The lack of a clear association between HDL cholesterol and the risk of hemorrhagic stroke in the general population may be because of low incident cases of hemorrhagic stroke. The present study found an inverse association between HDL cholesterol and hemorrhagic stroke risk among patients with type 2 diabetes mellitus, however, there was no further decrease in hemorrhagic stroke risk in the group with very high levels of HDL cholesterol. Another large cohort study from Denmark has also confirmed a U shaped association between HDL cholesterol and major CVD risk. 21 This is mainly because of the genetic variants in patients with extremely high HDL cholesterol levels. 22 These genetic variants may cause high incidence of the disease and share the genetic background of an extremely high HDL cholesterol phenotype. Further studies among patients with extremely high levels of HDL cholesterol are needed.
Although results about hemorrhagic stroke are controversial, reports of an association between HDL cholesterol and ischemic stroke risk are consistent in the general population. A Finnish study indicated an inverse association between HDL cholesterol and ischemic stroke. 20 Another study analyzing 185 genome-wide lipids-associated single nucleotide polymorphisms found that a 1-SD genetically elevated HDL cholesterol was associated with a decreased risk of small artery occlusion stroke. 23 Several underlying mechanisms of an increased stroke risk associated with low levels of HDL cholesterol may be proposed. HDL cholesterol has been found as a protective factor against atherosclerosis in animal studies. 17 It can reverse the cholesterol transport by exchanging its cholesteryl esters with triglycerides in very LDL or chylomicrons, causing a rapid clearance of the cholesteryl esters. 24 In addition, the functionality of HDL cholesterol seems to be as important as its levels in preventing atherosclerosis. 25 Increasing the levels as well as improving the functionality of HDL cholesterol may be a potential target in the pharmaceutical development.
The major strength of this study was the large sample size with rich clinical data, the latest data collected from patients with diabetes mellitus, and a high proportion of black participants. We reported the adjusted HRs for stroke among patients with type 2 diabetes mellitus, which provide important information for understanding the dose-response association of HDL cholesterol with stroke risk. The data we used derived from administrative databases, avoiding the problem of differential recall bias. Data in this study were extracted from 3 partners of REACHnet, which minimizes the influence of low accessibility of health care.
There are several limitations in our study. First, health system records were subject to misclassification. We were unable to evaluate the socioeconomic status of the study cohort because of lack of education level and family income information in the REACHnet EHR data infrastructure. Second, the stroke diagnoses in our study were based on physician diagnosis. However, most American and European cohort studies, such as the Kaiser Permanente Medical Care Program, 26 the Atherosclerosis Risk in Communities Study, 27 and the Framingham Study 28 have used the same method to diagnose stroke. The agreement with the diagnosis of stroke in these cohort studies is 75% to 90%. [27] [28] [29] Third, our analyses adjusted for some confounding factors, however, unmeasured factors such as family history of diabetes mellitus, other related chronic diseases, dietary factors, and physical activity status cannot be excluded. Finally, the information of HDL cholesterol subclasses was not complete in the dataset, so only HDL cholesterol levels were selected as the exposure.
Summary
In conclusion, the present study reported an inverse association between HDL cholesterol and the risks of total, ischemic and hemorrhagic stroke among patients with type 2 diabetes mellitus. This association is important to keep in mind when studying HDL cholesterol level and other cardiovascular risk factors in the patients with type 2 diabetes mellitus and when planning a strategy to prevent stroke.
